Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate Elevation
The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Myofibroblasts, the hallmark of fibrotic disease, contribute to the pathology of fibrosis by secreting large amounts of extracellular matrix and contributing to alveolar contraction. Myofibroblasts are characterized by the expression of α-smooth muscle actin (α-SMA), a contractile protein normally associated with smooth muscle cells. Transforming growth factor-β1 (TGF-β1) is a well characterized profibrotic cytokine that induces myofibroblast transformation both in vitro and in vivo. We report here that the lipid mediator prostaglandin E2 (PGE2) inhibits TGF-β1–induced expression of α-SMA in primary fetal and adult lung fibroblasts. This inhibition of α-SMA expression is associated with a reduction in the expression of collagen I. Inhibitory actions of PGE2 are mediated via E prostanoid receptor 2 (EP2) signaling, but not by EP3 signaling, and increases in cyclic adenosine monophosphate production. The inhibitory effects of PGE2 on TGF-β1–induced α-SMA expression are mimicked by an EP2 selective agonist, butaprost, and by forskolin-induced direct activation of adenyl cyclase. An EP2 antagonist blocks the inhibitory effects of PGE2, and an EP3 agonist does not inhibit TGF-β1–mediated increases in α-SMA expression. Our results demonstrate that PGE2 inhibits transition of fibroblasts to myofibroblasts by an EP2 receptor-activated pathway. Augmenting this pathway may serve as a potent antifibrotic therapeutic strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 has similar effects on formation and apoptosis in lung and keloid fibroblasts (145–147).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [147]
Citations
Cites
Desmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243 · cited 1×
“TGF-1 stimulates the expression of -SMA mRNA and protein in myofibroblasts (4, 6, 13 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 2×
“These findings support the prevailing hypothesis that fibrosis is the consequence of dysregulated repair after some form of lung injury ( 2 ).”
BackgroundKhalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.727 · Cited by 505 · cited 1×
“Numerous factors have been identified as promoting the transition of fibroblasts to myofibroblasts, specifically TGF-1, granulocyte macrophage-colony stimulating factor, heparin, and TNF- (12, 29 , 30).”
BackgroundZhang, K., Rekhter, M. D., Gordon, D., & Phan, S. H. (1994) · PubMed · Cited by 480
Wilborn, J., Crofford, L. J., Burdick, M. D., Kunkel, S. L., Strieter, R. M., & Peters-Golden, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117866 · Cited by 392 · cited 3×
“Moreover, fibroblasts cultured from idiopathic pulmonary fibrosis patients exhibit an impaired ability to synthesize PGE2 (21, 22 ), which has been attributed to an inability to appropriately upregulate COX-2 mRNA and protein levels (22, 35).”
BackgroundInfluentialSelf-citationCharacterization of a New Human Diploid Cell Strain, IMR-90
Nichols, W. W., Murphy, D. G., Cristofalo, V. J., Toji, L. H., Greene, A. E., & Dwight, S. A. (1977) · Science · doi:10.1126/science.841339 · Cited by 367 · cited 1×
“Definition of abbreviations: EP, E prostanoid receptor; RT-PCR, reverse transcriptase‐polymerase chain reaction. lung fibroblasts ( 24 ).”
Hansson, G. K., Hellstrand, M., Rymo, L., Rubbia, L., & Gabbiani, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.5.1595 · Cited by 268 · cited 3×
“Few factors have been identified that inhibit the transformation of myofibroblasts (5, 14 , 15, 31).”
BackgroundResultInfluentialFactors influencing myofibroblast differentiation during wound healing and fibrosis.
Desmoulière, A. (1995) · Cell Biology International · doi:10.1006/cbir.1995.1090 · Cited by 265 · cited 3×
“Among the -SMA inducing factors, TGF- 1i s thought to be the most efficient ( 12 ).”
BackgroundInfluentialKeerthisingam, C. B., Jenkins, R. G., Harrison, N. K., Hernandez-Rodriguez, N. A., Booth, H., Laurent, G. J., Hart, S. L., Foster, M. L., & McAnulty, R. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64092-8 · Cited by 241 · cited 2×
“Animal models have proven that pharmacologic or genetic blockade of prostaglandin production during the evolution of bleomycin-induced pulmonary fibrosis results in worse fibrotic outcomes ( 35 , 36).”
BackgroundZhang, H.-Y., Gharaee‐Kermani, M., Zhang, K., Karmiol, S., & Phan, S. H. (1996) · Europe PMC (PubMed Central) · Cited by 235
Research works printed but not linked: 13
- 2001, Chest, 120(1 Suppl), 77S
- 1981, Am. J. Pathol., 102, 427
- 1989, Lab. Invest., 60, 643
- 1996, Am. J. Pathol., 148, 527
- 1995, Exp. Nephrol., 3, 134
- 1994, Am. J. Pathol., 145, 114
- 1995, Am. J. Pathol., 147, 352
- 1996, Kidney Int. Suppl., 54, S46
- 1985, Am. Rev. Respir. Dis., 131, 94
- 1998, J. Cell. Biochem., 71, 254, 10.1002/(SICI)1097-4644(19981101)71:2<254::AID-JCB10>3.0.CO;2-L · doi:10.1002/(sici)1097-4644(19981101)71:2<254::aid-jcb10>3.0.co;2-l
- 1993, Am. J. Pathol., 143, 1754
- 1992, Lab. Invest., 67, 716
- 1995, J. Rheumatol., 22, 1876
Cited by
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression
Liu, F., Mih, J. D., Shea, B. S., Kho, A. T., Sharif, A. S., Tager, A. M., & Tschumperlin, D. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201004082 · Cited by 810
“Because PGE2 acts to suppress TGF-–driven responses in fibroblasts (Kolodsick et al., 2003; Sandulache et al., 2007; Thomas et al., 2007), the COX-2/PGE2 stimulation by TGF- is thought to dampen cellular responses to this fibrogenic cytokine and prevent overexuberant fibrotic reactions.”
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808
Self-citationMultifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 591
“PGE2 has been shown to inhibit myofibroblast differentiation and limit their collagen secretion during pulmonary fibrosis [60], in lung allografts [61], and in bleomycin-induced skin fibrosis [62].”
Diverse functions of matrix metalloproteinases during fibrosis
Giannandrea, M., & Parks, W. C. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.012062 · Cited by 541
“PGE2 suppresses fibrosis by inhibiting fibroblast migration, proliferation, collagen synthesis and differentiation into myofibroblasts (Huang et al., 2009; Kolodsick et al., 2003; White et al., 2005).”
BackgroundWoodward, D. F., Jones, R. L., & Narumiya, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003517 · Cited by 443
“It is noteworthy that EP2 receptors inhibit the transition of human lung fibroblasts to myofibroblasts, which are the hallmark of pulmonary fibrotic disease (Kolodsick et al., 2003).”
BackgroundCCR2-Mediated Recruitment of Fibrocytes to the Alveolar Space after Fibrotic Injury
Moore, B. B., Kolodsick, J. E., Thannickal, V. J., Cooke, K., Moore, T. A., Hogaboam, C., Wilke, C. A., & Toews, G. B. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62289-4 · Cited by 441
Self-citationMesenchymal Cells of the Intestinal Lamina Propria
Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X., & Mifflin, R. C. (2011) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100646 · Cited by 394
“Prostaglandin E2 (PGE2) inhibits fibroblast-myofibroblast transition through prostanoid EP2 receptors coupled to cyclic AMP (cAMP) production (47).”
BackgroundAronoff, D. M., Canetti, C., & Peters-Golden, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.559 · Cited by 360
“Western blots were performed as previously described (37).”
MethodSelf-citationEmerging cellular and molecular determinants of idiopathic pulmonary fibrosis
Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03693-7 · Cited by 351
“Finally, in vitro studies identified prostaglandin E2 (PGE2) as a regulator of fibroblast proliferation, differentiation and collagen synthesis [121, 122].”
BackgroundThe lung as a privileged site for the beneficial actions of PGE2
Vancheri, C. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.001 · Cited by 313
The Role of CCL12 in the Recruitment of Fibrocytes and Lung Fibrosis
Moore, B. B., Murray, L., Das, A., Wilke, C. A., Herrygers, A. B., & Toews, G. B. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0239oc · Cited by 309
Self-citationAn essential role for fibronectin extra type III domain A in pulmonary fibrosis
Muro, A. F., Moretti, F. A., Moore, B. B., Yan, M., Atrasz, R. G., Wilke, C. A., Flaherty, K. R., Martinez, F. J., Tsui, J. L., Sheppard, D., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1291oc · Cited by 297
“In support of these possibilities, Riquet and colleagues (29) and our own group (30) have shown that prostaglandin E2 is a potent suppressor of both a-SMA and Figure 6.”
BackgroundSelf-citationFibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis
Sakai, & Tager, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.001 · Cited by 285
“receptors, designated EP1, EP2, EP3, and EP4 [120], these inhibitory effects of PGE2 on fibroblasts are mediated by EP2 [120–122].”
The pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
“Studies in animal models have illustrated that inhibiting IL-13 function ameliorates lung fibrosis [Jakubzick et al. 2003; Kolodsick et al. 2003; Belperio et al. 2002], whereas overexpression of IL-13 promotes fibrosis [Lee et al.”
BackgroundSchmidt, M., Dekker, F. J., & Maarsingh, H. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.003707 · Cited by 267
“…the direct AC activator forskolin, and PDE inhibitors, suppress the transdifferentiation into myofibroblasts as indicated by a reduced expression of a-smooth muscle actin (Kolodsick et al., 2003; Liu et al., 2004; Baouz et al., 2005; Dunkern et al., 2007; Thomas et al., 2007; Lamyel et al., 2011).”
BackgroundCell traction force and measurement methods
Wang, J. H.-C., & Lin, J.-S. (2007) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-006-0068-4 · Cited by 264
“On the other hand, soluble factors such as bFGF, PGE2, and γ-interferon inhibit TGF-β1-upregulated α-SMA expression and thus likely cause the downregulation of CTF (Burgess et al. 2005; Hjelmeland et al. 2004; Kawai-Kowase et al. 2004; Kolodsick et al. 2003 ).”
BackgroundThe wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Boxall, C., Holgate, S. T., & Davies, D. E. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00130004 · Cited by 247
Aronoff, D. M., Canetti, C., Serezani, C. H., Luo, M., & Peters-Golden, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.595 · Cited by 241
“Western blots were performed as previously described (12).”
MethodSelf-citationSwaney, J. S., Roth, D. M., Olson, E. R., Naugle, J. E., Meszaros, J. G., & Insel, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408704102 · Cited by 226
Myofibroblast differentiation and survival in fibrotic disease
Kis, K., Liu, X., & Hagood, J. S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001967 · Cited by 224
Alveolar lipids in pulmonary disease. A review
Agudelo, C. W., Samaha, G., & Garcia-Arcos, I. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01278-8 · Cited by 202
“TGFβ stimulation of a human fibroblast cell line altered the expression of over 1000 genes, and treatment with PGE2 reversed multiple of these changes, especially those involved in the development of a myofibroblast phenotype [161, 162].”
BackgroundNovel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
“PGE2 exerts major anti-fibrotic effects by suppressing fibroblast responses, including proliferation (Bitterman et al., 1986; Lama et al., 2002), differentiation into myofibroblasts (Kolodsick et al., 2003) and collagen synthesis (Goldstein and Polgar, 1982).”
BackgroundInfluentialDiminished Prostaglandin E 2 Contributes to the Apoptosis Paradox in Idiopathic Pulmonary Fibrosis
Maher, T. M., Evans, I. C., Bottoms, S. E., Mercer, P. F., Thorley, A. J., Nicholson, A. G., Laurent, G. J., Tetley, T. D., Chambers, R. C., & McAnulty, R. J. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0674oc · Cited by 196
The Alveolar Macrophage: The Forgotten Cell in Asthma
Peters-Golden, M. (2004) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.f279 · Cited by 179
Self-citationHuang, S., Wettlaufer, S. H., Hogaboam, C., Aronoff, D. M., & Peters-Golden, M. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00232.2006 · Cited by 175
“Previous studies of EP receptor expression in IMR-90 cells used non-quantitative RT-PCR and have shown differing results in regards to relative EP receptor expression (4, 23).”
BackgroundResultInfluentialSelf-citationRout, U. K., Saed, G. M., & Diamond, M. P. (2005) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-3-1 · Cited by 176
“For instance, augmenting E prostanoid 2 (EP2) receptor pathways may be a way to reduce the incidence of adhesion formation because prostaglandin E2 (PGE2) is shown to inhibit TGF-β1 induced expression of α-SMA, production of Collagen I and the transformation of fibroblasts to myofibroblasts via EP2 signaling [45].”
Matrices of Physiologic Stiffness Potently Inactivate Idiopathic Pulmonary Fibrosis Fibroblasts
Marinković, A., Liu, F., & Tschumperlin, D. J. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0335oc · Cited by 163
Sisson, T. H., Ajayi, I. O., Subbotina, N., Dodi, A. E., Rodansky, E. S., Chibucos, L. N., Kim, K. K., Keshamouni, V. G., White, E. S., Zhou, Y., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.12.005 · Cited by 158
“Specifically, the antifibrotic eicosanoid prostaglandin E2 signals through the prostaglandin E receptor 2 to prevent TGF-b1emediated myofibroblast differentiation and collagen production, to increase myofibroblast susceptibility to Fas-mediated apoptosis, and to decrease fibroblast expression of the TGF-b1regulated in…”
BackgroundGrandoch, M., Roscioni, S. S., & Schmidt, M. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00458.x · Cited by 154
“, 2005) and differentiation of myofibroblasts (Kolodsick et al., 2003).”
BackgroundUnraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Prostaglandin E 2 induces fibroblast apoptosis by modulating multiple survival pathways
Huang, S. K., White, E. S., Wettlaufer, S. H., Grifka, H., Hogaboam, C. M., Thannickal, V. J., Horowitz, J. C., & Peters-Golden, M. (2009) · The FASEB Journal · doi:10.1096/fj.08-128801 · Cited by 147
Self-citationEpithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Horowitz, J., & Thannickal, V. (2006) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2006-957332 · Cited by 146
Self-citationBauman, K. A., Wettlaufer, S. H., Okunishi, K., Vannella, K. M., Stoolman, J. S., Huang, S. K., Courey, A. J., White, E. S., Hogaboam, C. M., Simon, R. H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38369 · Cited by 144
“Since autocrine expression of COX-2 and production of PGE2 are well known to inhibit fibroblast expression of the important matrix protein collagen I (15, 36), we also examined levels of collagen I protein and the α1 chain of procollagen I mRNA in these cell lysates.”
Self-citationThe role of periostin in lung fibrosis and airway remodeling
O’Dwyer, D. N., & Moore, B. B. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2649-z · Cited by 144
Self-citationHuang, S. K., Fisher, A. S., Scruggs, A. M., White, E. S., Hogaboam, C. M., Richardson, B. C., & Peters-Golden, M. L. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100446 · Cited by 152
Self-citationDunkern, T. R., Feurstein, D., Rossi, G. A., Sabatini, F., & Hatzelmann, A. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.036 · Cited by 150
Bleomycin-Induced E Prostanoid Receptor Changes Alter Fibroblast Responses to Prostaglandin E2
Moore, B. B., Ballinger, M. N., White, E. S., Green, M. E., Herrygers, A. B., Wilke, C. A., Toews, G. B., & Peters-Golden, M. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5644 · Cited by 135
“1-induced transformation of fibroblasts into myofibroblasts (13).”
BackgroundMethodSelf-citationProstaglandin E2 and the Pathogenesis of Pulmonary Fibrosis
Bozyk, P. D., & Moore, B. B. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0025rt · Cited by 152
Self-citationWhite, E. S., Atrasz, R. G., Dickie, E. G., Aronoff, D. M., Stambolic, V., Mak, T. W., Moore, B. B., & Peters-Golden, M. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0126oc · Cited by 131
“In addition to migration, PGE2 modulates a number of other fibroblast functions central to the fibrotic response, including proliferation (9), myofibroblast transdifferentiation (29), and collagen production (29,42).”
BackgroundResultSelf-citationCOX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis
Lovgren, A. K., Jania, L. A., Hartney, J. M., Parsons, K. K., Audoly, L. P., FitzGerald, G. A., Tilley, S. L., & Koller, B. H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00492.2005 · Cited by 128
“Other studies have shown that PGE2 is capable of inhibiting fibroblast migration and fibroblast to myofibroblast transition (26, 28).”
BackgroundHuang, S. K., Wettlaufer, S. H., Chung, J., & Peters-Golden, M. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0080oc · Cited by 126
“Among the many antifibrotic actions of PGE2 is its ability to directly inhibit multiple fibroblast functions, including cell proliferation (9), collagen I synthesis (10, 11), and myofibroblast differentiation ( 12 ).”
BackgroundSelf-citationReversal of Myofibroblast Differentiation by Prostaglandin E2
Garrison, G. W., Huang, S. K., Okunishi, K., Scott, J. P., Penke, L. R. K., Scruggs, A. M., & Peters-Golden, M. L. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0262oc · Cited by 126
“The inhibition of fibroblast proliferation (16), collagen expression (16), and myofibroblast differentiation (19) by PGE2 has been shown to occur via ligation of the EP2 receptor, which is the most abundantly expressed receptor in fibroblasts (16).”
BackgroundInfluentialSelf-citationLung Pericytes and Resident Fibroblasts
Barron, L., Gharib, S. A., & Duffield, J. S. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.004 · Cited by 143
Hodges, R. J., Jenkins, R. G., Wheeler-Jones, C. P. D., Copeman, D. M., Bottoms, S. E., Bellingan, G. J., Nanthakumar, C. B., Laurent, G. J., Hart, S. L., Foster, M. L., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63423-2 · Cited by 125
Tumor-Secreted LOXL2 Activates Fibroblasts through FAK Signaling
Barker, H. E., Bird, D., Lang, G., & Erler, J. T. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0033-t · Cited by 119
FOXM1 is a critical driver of lung fibroblast activation and fibrogenesis
Penke, L. R. K., Speth, J. M., Dommeti, V. L., White, E. S., Bergin, I. L., & Peters-Golden, M. L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci87631 · Cited by 126
Self-citationLiu, X., Ostrom, R. S., & Insel, P. A. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00461.2003 · Cited by 117
“(28) suggest that PGE2-stimulated cAMP production prevents myofibroblast differentiation and inhibits production of ECM by pulmonary fibroblasts.”
BackgroundResultInfluentialProstaglandin E2 Inhibits Eosinophil Trafficking through E-Prostanoid 2 Receptors
Sturm, E. M., Schratl, P., Schuligoi, R., Kónya, V., Sturm, G. J., Lippe, I. T., Peskar, B. A., & Heinemann, Á. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7273 · Cited by 117
“Moreover, activation of EP2 receptors protects against pulmonary fibrosis (22, 56), which might be of additional value with respect to airway remodeling in asthma.”
BackgroundMatrix Metalloproteinase-19 Is a Key Regulator of Lung Fibrosis in Mice and Humans
Yu, G., Kovkarova-Naumovski, E., Jara, P., Parwani, A., Kass, D., Ruiz, V., Lopez-Otín, C., Rosas, I. O., Gibson, K. F., Cabrera, S., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0302oc · Cited by 116
Chapter 7 Mechanobiology of Adult and Stem Cells
Wang, J. H., & Thampatty, B. P. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01207-0 · Cited by 128
Critical Role of Serum Response Factor in Pulmonary Myofibroblast Differentiation Induced by TGF-β
Sandbo, N., Kregel, S., Taurin, S., Bhorade, S., & Dulin, N. O. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0288oc · Cited by 105
“Other investigators have shown that PGE2 elicits its antifibrotic effect via elevation of cAMP, and this effect is independent of Smad signaling (17, 18).”
BackgroundStreptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin
Knippenberg, S., Ueberberg, B., Maus, R., Bohling, J., Ding, N., Tort Tarres, M., Hoymann, H.-G., Jonigk, D., Izykowski, N., Paton, J. C., et al. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206420 · Cited by 99
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 115
“In human lung fibroblasts, cAMP activation can limit proliferation and ECM differentiation (83).”
BackgroundThomas, P. E., Peters-Golden, M. L., White, E. S., Thannickal, V. J., & Moore, B. B. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00489.2006 · Cited by 100
“This is particularly true for lung fibrosis, since lung fibroblast activation is downregulated by PGE2 (21, 28, 46) and since fibroblasts isolated from fibrotic lung show deficits in PGE2 synthesis (19, 43, 47) and reduced expression of cyclooxygenase-2 (42, 47).”
BackgroundMethodInfluentialSelf-citationSandulache, V. C., Parekh, A., Li‐Korotky, H., Dohar, J. E., & Hebda, P. A. (2007) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2006.00193.x · Cited by 91
“In vitro experiments in various tissue types support these findings, demonstrating putative PGE2 antifibrotic effects, such as the reversal of the fibroblast to myofibroblast transition induced by transforming growth factor (TGF)-b1.(19) The role of PGE2 signaling in keloid formation remains unclear for two reasons.”
BackgroundInfluentialMyofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions
Fortier, S. M., Penke, L. R. K., King, D., Pham, T. X., Ligresti, G., & Peters-Golden, M. L. (2021) · JCI Insight · doi:10.1172/jci.insight.144799 · Cited by 101
“We have shown previously that PGE 2 prevents TGF-β –induced fibroblast differentiation mainly by activation of the EP2 receptor, which stimulates adenylyl cyclase to increase production of intracellular cAMP and activate protein kinase A (PKA) (17–19).”
InfluentialSelf-citationDing, Q., Gladson, C. L., Wu, H., Hayasaka, H., & Olman, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803645200 · Cited by 91
Aronoff, D. M., Peres, C. M., Serezani, C. H., Ballinger, M. N., Carstens, J. K., Coleman, N., Moore, B. B., Peebles, R. S., Faccioli, L. H., & Peters-Golden, M. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1628 · Cited by 90
Self-citationClapp, L. H., & Gurung, R. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.04.007 · Cited by 101
“[108] Kolodsick JE, Peters-Golden M, Larios J, Toews GB, Thannickal VJ, Moore BB.”
O'Dwyer, D. N., Ashley, S. L., & Moore, B. B. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00221.2016 · Cited by 88
Self-citationSato, M., & Keshavjee, S. H. (2008) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2008.05.002 · Cited by 95
Penke, L. R. K., Huang, S. K., White, E. S., & Peters-Golden, M. L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558130 · Cited by 95
“We have previously found that the G s-coupled receptor EP2 is the most abundantly expressed in human lung fibroblasts and, via increases in cAMP, is largely responsible for most of the anti-fibrotic actions of PGE2, including its ability to inhibit myofibroblast differentiation (29).”
BackgroundSelf-citationProstaglandin E2protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction
Dackor, R. T., Cheng, J., Voltz, J. W., Card, J. W., Ferguson, C. D., Garrett, R. C., Bradbury, J. A., DeGraff, L. M., Lih, F. B., Tomer, K. B., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00176.2011 · Cited by 90
“For example, PGE2 has been shown to inhibit fibroblast proliferation and collagen synthesis, regulate wound closure in airway epithelium, and inhibit TGF- induced fibroblast to myofibroblast transition (35, 47).”
BackgroundCardiac Fibroblasts in Cell Culture Systems: Myofibroblasts All Along?
Rohr, S. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182137e17 · Cited by 80
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Zarrin, V., Moghadam, E. R., Hashemi, F., Makvandi, P., Samarghandian, S., Khan, H. Z., Hashemi, F., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585413 · Cited by 87
“The prostaglandin E2 (PGE2) is formed by cyclooxygenase metabolism of arachidonic acid and inhibits the migration and proliferation of myofibroblasts, and ECM accumulation (Elias et al., 1985; Bitterman et al., 1986; Fine et al., 1989; Kolodsick et al., 2003; White et al., 2005; Huang et al., 2009).”
BackgroundBeurden, H. E. V., den Hoff, J. W. V., Torensma, R., Maltha, J. C., & Kuijpers‐Jagtman, A. M. (2005) · Journal of Dental Research · doi:10.1177/154405910508401002 · Cited by 90
Eicosanoids: mediators and therapeutic targets in fibrotic lung disease
Charbeneau, R. P., & Peters-Golden, M. L. (2005) · Clinical Science · doi:10.1042/cs20050012 · Cited by 79
Self-citationVariable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia
Huang, S. K., Wettlaufer, S. H., Hogaboam, C. M., Flaherty, K. R., Martínez, F. J., Myers, J. L., Colby, T. V., Travis, W. D., Toews, G. B., & Peters-Golden, M. L. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-963oc · Cited by 83
“PGE2 inhibits fibroblast migration (20, 21), proliferation (22, 23), collagen synthesis (24, 25), and myofibroblast differentiation ( 26 ).”
BackgroundSelf-citationNakagawa, N., Yuhki, K., Kawabe, J.-I., Fujino, T., Takahata, O., Kabara, M., Abe, K., Kojima, F., Kashiwagi, H., Hasebe, N., et al. (2012) · Kidney International · doi:10.1038/ki.2012.115 · Cited by 75
Peres, C. M., Aronoff, D. M., Serezani, C. H., Flamand, N., Faccioli, L. H., & Peters-Golden, M. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5454 · Cited by 78
“Western blotting was performed as previously described (21).”
MethodSelf-citationWomen have better long-term prognosis than men after cardiac resynchronization therapy
Zabarovskaja, S., Gadler, F., Braunschweig, F., Ståhlberg, M., Hörnsten, J., Linde, C. M., & Lund, L. H. (2012) · EP Europace · doi:10.1093/europace/eus039 · Cited by 82
Determinants of initiation and progression of idiopathic pulmonary fibrosis
Kottmann, R. M., Hogan, C. M., Phipps, R. P., & Sime, P. J. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01624.x · Cited by 74
Zhang, A., Wang, M.-H., Dong, Z., & Yang, T. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00480.2005 · Cited by 73
“In cultured lung fibroblasts, PGE2 suppresses cell proliferation (13), collagen production (14, 24), and fibroblast-to-myofibroblast transition (20).”
Defect of Hepatocyte Growth Factor Secretion by Fibroblasts in Idiopathic Pulmonary Fibrosis
Marchand-Adam, S., Marchal-Sommé, J., Cohen, M., Soler, P., Gérard, B., Castier, Y., Lesèche, G., Valeyre, D., Mal, H., Aubier, M., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200212-1514oc · Cited by 73
Aronoff, D. M., Carstens, J. K., Chen, G.-H., Toews, G. B., & Peters-Golden, M. L. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.827 · Cited by 71
Self-citationReversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation
Wettlaufer, S. H., Scott, J. P., McEachin, R. C., Peters-Golden, M. L., & Huang, S. K. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0468oc · Cited by 76
“Work from our laboratory has shown that not only does PGE2 prevent fibroblast differentiation into myofibroblasts (17), but it also reverses TGF-b1 and endothelin-1–induced myofibroblast differentiation (12).”
BackgroundMethodSelf-citationPDE4 inhibitors roflumilast and rolipram augment PGE 2 inhibition of TGF-β1-stimulated fibroblasts
Togo, S., Liu, X., Wang, X., Sugiura, H., Kamio, K., Kawasaki, S., Kobayashi, T., Ertl, R. F., Ahn, Y., Holz, O., et al. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00508.2007 · Cited by 80
“In this context, PGE can inhibit many profibrotic fibroblast functions including chemotaxis (21), proliferation (5, 17), matrix production (17, 40), differentiation (24, 47), and matrix contraction (30).”
BackgroundMyofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective
Gerarduzzi, C., & Battista, J. A. D. (2016) · Inflammation Research · doi:10.1007/s00011-016-1019-x · Cited by 76
The Roles of Various Prostaglandins in Fibrosis: A Review
Li, K., Zhao, J., Wang, M., Niu, L., Wang, Y., Li, Y., & Zheng, Y. (2021) · Biomolecules · doi:10.3390/biom11060789 · Cited by 71
“Many studies have shown that PGE2 exerts antifibrotic effects on different organs by inhibiting cell proliferation [25,26], migration [27], collagen expression and deposition [25,28,29], and fibroblast differentiation [30,31] by activating the cAMP/PKA signaling pathway upon binding to EP2 or EP4 in fibroblasts.”
BackgroundMurakami, S., Nagaya, N., Itoh, T., Kataoka, M., Iwase, T., Horio, T., Miyahara, Y., Sakai, Y., Kangawa, K., & Kimura, H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00042.2005 · Cited by 67
“inhibitor peptide sequence ( 14-22 ) cell-permeable (10-6 M) (Calbiochem, Cambridge,”
BackgroundAclidinium inhibits human lung fibroblast to myofibroblast transition
Milara, J., Serrano, A., Peiró, T., Gavaldà, A., Miralpeix, M., Morcillo, E. J., & Cortijo, J. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200376 · Cited by 65
Kowal‐Bielecka, O., Kowal, K., Distler, O., Rojewska, J., Bodzenta‐Łukaszyk, A., Michel, B. A., Gay, R. E., Gay, S., & Sierakowski, S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21432 · Cited by 62
White, K. E., Ding, Q., Moore, B. B., Peters-Golden, M. L., Ware, L. B., Matthay, M. A., & Olman, M. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.637 · Cited by 65
Self-citationIdiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 69
Functional Prostaglandin-Endoperoxide Synthase 2 Polymorphism Predicts Poor Outcome in Sarcoidosis
Hill, M., Papafili, A., Booth, H., Lawson, P. J., Hubner, M., Beynon, H., Read, C., Lindahl, G. E., Marshall, R. P., McAnulty, R. J., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1839oc · Cited by 60
“The genotype frequencies in the control subjects are similar to those we previously reported ( 13 ).”
ResultWarsinske, H., DiFazio, R. M., Linderman, J. J., Flynn, J. L., & Kirschner, D. E. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.06.017 · Cited by 67
Corrigan, C. J., Napoli, R. L., Meng, Q., Fang, C., Wu, H., Tochiki, K. K., Reay, V., Lee, T. H., & Ying, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.007 · Cited by 59
Protease‐activated receptors and prostaglandins in inflammatory lung disease
Peters, T., & Henry, P. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00449.x · Cited by 58
“EP2 receptor activation by PGE2 inhibits fibroblast proliferation and migration, transition to myofibroblast and collagen synthesis (Kolodsick et al., 2003; Moore et al., 2005; White et al., 2005).”
Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis
Coward, W. R., Brand, O. J., Pasini, A., Jenkins, G. R., Knox, A. J., & Pang, L. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0286oc · Cited by 57
“TGF-b1 is a major activator of lung fibroblasts both in vitro (19) and in vivo (20).”
BackgroundJensen, M. S., Mutsaers, H. A. M., Tingskov, S. J., Christensen, M. S., Madsen, M. G., Olinga, P., Kwon, T., & Nørregaard, R. (2019) · Acta Physiologica · doi:10.1111/apha.13291 · Cited by 59
Bärnthaler, T., Theiler, A., Zabini, D., Trautmann, S., Stacher‐Priehse, E., Lanz, I., Klepetko, W., Sinn, K., Flick, H., Scheidl, S. J., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.032 · Cited by 61
Wu, Y., Karna, S., Choi, C. H., Tong, M., Tai, H.-H., Na, D. H., Jang, C. H., & Cho, H. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200390u · Cited by 55
Epa, A. P., Thatcher, T. H., Pollock, S. J., Wahl, L. A., Lyda, E., Kottmann, R. M., Phipps, R. P., & Sime, P. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135266 · Cited by 61
Aspirin-Sensitive Respiratory Disease
Farooque, S. P., & Lee, T. H. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163114 · Cited by 57
Zhao, J., Shu, B., Chen, L., Tang, J., Zhang, L., Xie, J., Liu, X., Xu, Y., & Qi, S. (2016) · Experimental Dermatology · doi:10.1111/exd.13014 · Cited by 64
Sandulache, V. C., Parekh, A., Li‐Korotky, H., Dohar, J. E., & Hebda, P. A. (2006) · Wound Repair and Regeneration · doi:10.1111/j.1743-6109.2006.00156.x · Cited by 54
“Protein bands were found to run at the expected molecular weights, as previously reported.(22,26) Analysis of multiple immunoblots revealed no significant difference in the levels of EP receptor expression between the two fibroblast types (data not shown).”
ResultTransforming growth factor‐beta 1 pathways in inflammatory airway diseases
Yang, Y., Zhang, N., Lan, F., Crombruggen, K. V., Fang, L., Hu, G., Hong, S., & Bachert, C. (2014) · Allergy · doi:10.1111/all.12403 · Cited by 60
“As an antifibrotic PG, PGE2 has been shown to play a beneficial role in fibrotic lung diseases with an increased cyclic adenosine 30,50-monophosphate (cAMP), which in turn can inhibit TGF-b-induced myofibroblast differentiation and limit collagen secretion by a Smad-independent signaling (48).”
BackgroundAirway remodeling in murine asthma correlates with a defect in PGE2synthesis by lung fibroblasts
Stumm, C. L., Wettlaufer, S. H., Jancar, S., & Peters-Golden, M. L. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00158.2011 · Cited by 53
Self-citation
Metadata
- Authors
- Kolodsick, J. E., Peters-Golden, M., Larios, J., Toews, G. B., Thannickal, V. J., & Moore, B. B.
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Pulmonary and Critical Care Medicine Division, University of Michigan School of Medicine, Ann Arbor, Michigan
- Corresponding author
- Moore, Bethany B.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 29
- Issue
- 5
- Pages
- 537-544
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W1995721099
- Cited by
- 294
- References
- 37
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 7 · 2020: 11 · 2019: 15 · 2018: 16 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 19 · 2013: 16 · 2012: 15
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ca079046-03)
- National Heart, Lung, and Blood Institute (P50HL56402, HL071586, P50HL056402, P50HL60289, 2T32HL07749, R01HL071586, P50HL060289, T32HL007749)
- National Cancer Institute (CA79046)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- prostaglandin E2, myofibroblast differentiation, cyclic AMP, TGF-β1, alpha-smooth muscle actin, type I collagen, pulmonary fibrosis, antifibrotic therapy, butaprost, adenylate cyclase
- MeSH terms
- Cyclic AMP, Cell Differentiation, Fibroblasts, Colforsin, Humans, Dinoprostone, Receptors, Prostaglandin E
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.